Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

map of United States of America with medicine pills and white background

Manufacturing

Trump’s Reshoring Drive Raises Questions About Supply Resilience

Some observers see risks to becoming over-reliant on local facilities, noting the potential need for trade partners if domestic production is disrupted.

September 16, 2025

4 min read

Nick Paul Taylor

External view of Novartis' office in Massachusetts

Collaboration

Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B

Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.

September 15, 2025

2 min read

Tristan Manalac

Adcomms

FDA Flip-Flops on Scrapping Adcomms

CDER Director George Tidmarsh said on two separate events last week that he thought advisory committee meetings for specific drug applications were redundant, but then denied having said the agency would abandon them.

September 15, 2025

2 min read

Tristan Manalac

Pictured: AstraZeneca's manufacturing facility in Sweden

Europe

AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility

AstraZeneca in January also stopped its $610 million plans to construct a vaccine R&D and manufacturing site in the U.K.

September 15, 2025

2 min read

Tristan Manalac

Sponsored

Rosnilimab Shows Promise as a Potential Next-Generation RA Therapy

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study

September 15, 2025

7 min read

Antibodies, immunoglobulin Ig proteins 3D medical image. Immune system, IgM, IgG, IgE, IgD, IgA antibodies glycoproteins, specific antigens against virus. Vital components of the immunity responce

Immunology and inflammation

Rush of Targeted Myasthenia Gravis Therapies Hit Once Sparse Market

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and several companies, including argenx and Regeneron, have recently released promising late-stage trial results.

September 15, 2025

6 min read

Amanda Heidt

Cityscape image of Vienna with the Vienna State Opera during sunset.

Obesity

EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More

While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told BioSpace the conference will also provide important insights into the therapeutic benefits of incretin therapies beyond weight loss.

September 15, 2025

6 min read

Tristan Manalac